Panelists discuss how advanced practice providers (APPs) serve as crucial touchpoints throughout the journey of patients with chronic myeloid leukemia (CML), offering more accessible communication, early identification of adverse effects, medication management support, and integration of comprehensive supportive care services that collectively reduce emotional and logistical stress while improving overall quality of life.

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.

Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older nilotinib formulation that showed increased cardiotoxicity in long-term trials, though it remains unclear whether this was directly related to poor adherence to fasting guidelines or inherent to the medication's pharmacological properties.

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant unmet need in chronic myeloid leukemia (CML) treatment by reducing disruption to patients' daily lives, potentially improving medication adherence and overall quality of life for patients who otherwise face a normal life expectancy when their condition is properly controlled.

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.

The intersection of cardiology and oncology is greater than nurses and providers may assume, explained 2 experts.

Sessions addressing supportive care needs for patients with cancer on early phase clinical trials appeared feasible and acceptable in a prospective study.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.

Assessment of psychological needs and offering tailored interventions immediately after BCS helps patients with breast cancer in the outpatient setting.

Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the necessity of toxicity monitoring.

Authors noted that BiTEs have expanded the treatment paradigms for several types of solid tumors and blood cancers; however, toxicities associated with this class of agents have raised safety concerns.

Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.